Market Overview

UPDATE: Citigroup Initiates Ariad Pharmaceuticals at Buy

Related ARIA
Watch These 10 Huge Put Purchases In Tuesday Trade
Benzinga's Option Alert Recap From January 30

Citigroup initiated coverage on Ariad Pharmaceuticals (NASDAQ: ARIA) with a Buy rating and a $31 price target.

Citigroup noted, "We believe ARIA's ponatinib is "best in class" in the ~$5bn WW leukemia (CML) market and our outlook is higher than consensus. Initial FDA/EU ponatinib approvals are widely expected by 1Q:13 and 2H:13 respectively, but a potential broader drug label would be upside to consensus, in our view. We expect ponatinib's Ph3 1st-line CML trial will stop early (2014) adding an additional ~$400M in 1st-line sales by 2018. We believe ARIA's lung cancer drug AP26113 is superior to PFE's Xalkori (crizotinib). Its dual mechanism also targets other lung cancer populations >3X crizotinib's market. With crizotinib `15 consensus estimates reaching ~$700M, our 2017 risk-adjusted AP26113 sales estimate of $240M is not a stretch."

Ariad Pharmaceuticals closed at $21.97 on Thursday.

Latest Ratings for ARIA

Jan 2017SunTrust Robinson HumphreyDowngradesBuyHold
Jan 2017JefferiesDowngradesBuyHold
Jan 2017BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (ARIA)

View Comments and Join the Discussion!